- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03233035
Low Dose Ketamine Intra Nasal Traumatology (Ket)
Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial
Study Overview
Detailed Description
Intranasal ketamine for treatment of acute pain in the emergency department : A randomized controlled trial
Introduction :
Pain is the most common complaint for emergency department (ED) visits [1].The provision of adequate, safe, and timely analgesia is a core component of patient care in the emergency department (ED). Ketamine is a noncompetitive Nmethyl- D-aspartate and glutamate receptor antagonist that decreases central sensitization, "wind-up" phenomena, and pain memory [2,3].
At subdissociative doses (0.1 to 0.6 mg/kg; most commonly 0.3 mg/kg) maintains potent analgesic and amnestic effects that are accompanied by preservation of protective airway reflexes, spontaneous respiration, and cardiopulmonary stability [4-6].
Intranasal route ….
Objective of the study :
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or class III analgesic agents.
Materials and Methods :
Study design :
It is a ramdomized, prospective, double blind, controlled, multicentric trial. The study is registered with clinical.tria.gov (…….).
Study Setting and Selection of Participants :
The trial is conducted in three community teaching hospitals :
- Emergency department, fattouma bourguiba university hospital, monastir, tunisia
- Emergency department, sahloul university hospital, sousse, tunisia
- Emergency department, farhat hached university hospital, sousse, tunisia
ED principal investigators maintain the randomization list, which is generated before the start of the study, prepare the medication, and deliver it to the treating physician in a blinded manner.
Inclusion criteria :
The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analogue scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Exclusion criteria :
- Pregnancy,
- Breast-feeding,
- Altered mental status,
- Allergy to ketamine or morphine or
- Weight less than 46 kg or greater than 115 kg,
- Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
- Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
- Alcohol or drug abuse,
- Psychiatric illness,
- Recent (4 hours before) analgesic agent use.
Protocol :
In the triage area, each patient having the inclusion criteria receives 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril or 0.5 mL of normal saline solution in one pulverisation per nostril as a placebo according to the predetermined randomization list. None of the treating physician or nurses is aware about the medication received. In all patients included, the investigators collect vital signs ; demographic and clinical data.
Study investigators record VAS, and adverse effects at 15, 30, 60, 90, and 120 minutes.
At 30 minutes, if patients report a pain numeric rating scale score of 5 or greater and request additional pain relief, titrated morphine is administered as a rescue analgesic with a dose of 0.1 mg/Kg repeated every 3 to 5 minutes if the pain numeric rating scale score is still greater or equal to 3.
All data recorded on data collection sheets, including sex, demographics, medical history, and vital signs, were entered into SPSS (version 20.0; IBM Corp) by the research manager.
Patients's informed consent is obtained. The ethic commitee of our institution approved the study.
Endpoints :
Primary endpoints :
- Need for rescue opioids during ED stay
Secondary endpoints :
- requirement of non-opioids analgesic agents.
- percentage of patients discharged from the ED with VAS <30.
- Safety : adverse events
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Monastir, Tunisia, 5000
- Emergency department of university hospital Fattouma Bourguiba of Monastir
-
-
Emergency Department Monastir, Tunisia 5000
-
Monastir, Emergency Department Monastir, Tunisia 5000, Tunisia, 5000
- Nouira Samir
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Exclusion Criteria:
- - Pregnancy,
- Breast-feeding,
- Altered mental status,
- Allergy to ketamine or morphine or
- Weight less than 46 kg or greater than 115 kg,
- Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
- Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
- Alcohol or drug abuse,
- Psychiatric illness,
- Recent (4 hours before) analgesic agent use.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: placebo group
Intranasal placebo pulverisation
|
0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
Other Names:
|
ACTIVE_COMPARATOR: Ketamine group
Intranasal ketamine pulverisation
|
25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and percentage of patients who need rescue opiods in the two groups
Time Frame: 30 minutes
|
the need for rescue opioids during ED stay
|
30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intolerance to treatement and adverse events
Time Frame: 30 minutes and at 120 minutes
|
Noticing any sign of intolerance due to treatement : Dizziness , Vomiting..
|
30 minutes and at 120 minutes
|
Percentage of patients with VAS <30 mm at discharge
Time Frame: 120 minutes
|
percentage of patients discharged from the ED with VAS <30.
|
120 minutes
|
Number and percentage of patients who required non opiods analgesics
Time Frame: 30 minutes
|
Requirement of non-opioids analgesic agents
|
30 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Acute Pain
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- Ket-Int-Nas-TR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trauma
-
Humacyte, Inc.Active, not recruitingTrauma | Trauma Injury | Trauma, Multiple | Trauma BluntUkraine
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedTrauma Injury | Trauma, MultipleTurkey
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaRecruitingTrauma Injury | Trauma, MultipleKorea, Republic of
-
Rabin Medical CenterIsraeli Ministry of SecurityUnknown
-
University Hospital, AngersRecruiting
-
Chang, Steve S., M.D.Santa Barbara Cottage Hospital; Accumetrics, Inc.CompletedHead Injury Trauma BluntUnited States
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Assistance Publique - Hôpitaux de ParisFrancophone Pediatric Resuscitation and Emergency Group (GFRUP)Completed
-
Norwegian University of Science and TechnologySt. Olavs HospitalTerminatedTrauma, Multiple | Trauma Severity Indices | Injuries, Multiple | Norway/Epidemiology | Trauma Centers/Statistics & Numerical Data
-
Fundacion Clinica Valle del LiliUniversity of Pittsburgh; Hospital Universitario del Valle Evaristo GarciaRecruitingTrauma | Trauma Injury | Trauma, MultipleColombia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States